Dry Age Related Macular Degeneration (AMD) Market Size and Share Analysis - Growth Trends and Forecasts (2025-2032)

Market Size and Trends

The Dry Age Related Macular Degeneration (AMD) market is estimated to be valued at USD 4.7 billion in 2025 and is expected to reach USD 8.9 billion by 2032, growing at a compound annual growth rate (CAGR) of 9.4% from 2025 to 2032. This growth reflects increasing prevalence of AMD globally, rising awareness, and advancements in diagnostic and treatment technologies driving market expansion over the forecast period.

Market trends indicate a significant shift towards innovative therapies, including the development of novel drug delivery systems and personalized medicine approaches targeting dry AMD. Additionally, the growing geriatric population, along with increasing investment in research and development by leading pharmaceutical companies, is fueling market growth. Enhanced screening programs and rising healthcare infrastructure in emerging economies further contribute to the optimistic market outlook.

Segmental Analysis:

By Therapeutic Type: Dominance of Nutritional Supplements Driven by Preventive and Supportive Care Focus

In terms of By Therapeutic Type, Nutritional Supplements contributes the highest share of the Dry Age Related Macular Degeneration (AMD) market owing to the growing emphasis on preventive care and disease management through non-invasive interventions. Patients and healthcare providers increasingly favor nutritional supplementation because it offers a safer, accessible, and cost-effective approach to slowing the progression of Dry AMD, which currently has limited curative options. The widespread use of vitamins, antioxidants, and minerals that support retinal health aligns well with patient preferences for managing a chronic, degenerative condition with minimal side effects. Additionally, supportive evidence from landmark studies highlighting the benefits of specific nutrient combinations in reducing disease advancement has elevated the credibility and adoption of this segment. The aging global population, particularly among those at higher risk of AMD, further fuels demand for nutritional therapies as first-line or complementary measures. Moreover, these supplements are often recommended by ophthalmologists as part of a holistic treatment regimen addressing lifestyle factors such as diet and smoking cessation. The convenience of oral administration and availability over the counter also expands market penetration beyond clinical settings, enabling a broader demographic reach. While other therapeutic types, including Anti-VEGF therapies and emerging treatments like Complement Inhibitors and Stem Cell Therapy, offer promising benefits, their invasive nature, higher costs, and developmental constraints currently limit widespread use compared to Nutritional Supplements. Together, these factors consolidate Nutritional Supplements as the cornerstone therapy segment within Dry AMD management.

By Diagnostic Modality: Fundus Photography Leading Due to Accessibility and Comprehensive Retinal Imaging

In terms of By Diagnostic Modality, Fundus Photography holds the largest share in the diagnosis and monitoring of Dry AMD, primarily because of its ability to provide detailed, high-resolution images of the retina in a cost-effective and non-invasive manner. This modality enables early detection of characteristic drusen deposits and retinal pigment epithelial changes, which are critical markers in Dry AMD progression. Fundus cameras are widely available in both primary eye care and specialty clinics, making this diagnostic tool accessible to a broad patient base. The simplicity and relatively rapid image acquisition facilitate routine screening and longitudinal patient monitoring, both essential for managing a chronic, slowly progressive condition such as Dry AMD. Furthermore, advances in digital imaging and teleophthalmology integration have enhanced the usability of fundus photography by enabling remote consultations and centralized data analysis, thereby expanding reach to underserved areas. Compared to more complex and expensive diagnostic techniques like Optical Coherence Tomography (OCT) or Fluorescein Angiography, fundus photography presents a practical alternative for baseline and follow-up assessments. Although OCT provides cross-sectional retinal layer details, its higher cost and technical requirements limit universal accessibility, particularly in resource-constrained settings. These factors collectively contribute to the dominant market position of fundus photography within diagnostic modalities for Dry AMD, making it a foundational technology in early disease detection and ongoing patient evaluation.

By End User: Hospitals & Clinics Drive Market Growth Through Comprehensive Care Delivery

In terms of By End User, Hospitals & Clinics contribute the highest share of the Dry AMD market due to their role as primary hubs for diagnosis, treatment, and ongoing management of patients with this condition. These settings benefit from multidisciplinary teams that include ophthalmologists, retina specialists, and support staff, enabling comprehensive care workflows essential for the complex monitoring and therapeutic requirements of AMD patients. Hospitals and clinics are equipped with advanced imaging technologies and therapeutic facilities that allow them to provide both diagnostic services, such as fundus photography and OCT, and treatment administration, including nutritional counseling and emerging interventional therapies. The presence of standardized care protocols and electronic health record systems further facilitates coordinated patient management and outcome tracking, improving adherence to clinical guidelines. In addition, hospitals and clinics serve as referral centers from primary care and community eye care providers, positioning them as critical access points for patients requiring specialized Dry AMD care. The ability to offer patient education and support services within these settings also enhances patient engagement and compliance, which are vital for effective disease management over time. Although specialty eye care centers and home healthcare settings are growing in importance, the broad scope of capabilities and infrastructure concentrated in hospitals and clinics ensures their continued dominance as the key end user segment in the Dry AMD market.

Regional Insights:

Dominating Region: North America

In North America, the dominance in the Dry Age Related Macular Degeneration (AMD) market is largely driven by a well-established and sophisticated healthcare ecosystem, substantial government investment in healthcare infrastructure, and a high prevalence of aging populations requiring advanced ophthalmic care. The presence of advanced diagnostic facilities, strong reimbursement frameworks, and extensive clinical research activity further solidify its leadership position. The U.S. Food and Drug Administration's (FDA) streamlined drug and device approval processes encourage innovation and the commercialization of novel therapies for Dry AMD, enhancing market offerings. Furthermore, North America hosts several global pharmaceutical and biotech giants such as Novartis AG, Regeneron Pharmaceuticals, and Allergan (an AbbVie company), whose extensive portfolios and ongoing R&D initiatives significantly contribute to the market's maturity and depth. Strong collaborations between research institutes, hospitals, and private sector players drive continuous advancement in treatment options, solidifying North America as the epicenter of technological and therapeutic innovation for Dry AMD.

Fastest-Growing Region: Asia Pacific

Meanwhile, the Asia Pacific region exhibits the fastest growth in the Dry Age Related Macular Degeneration market propelled by rapid demographic shifts, increasing awareness regarding eye health, and improving healthcare infrastructure. Governments in key countries, including China, Japan, and South Korea, have implemented favorable policies aimed at enhancing accessibility to advanced eye care and promoting domestic pharmaceutical innovation, which is catalyzing market expansion. Trade dynamics, including increased cross-border collaborations and technology transfers from Western markets, are accelerating the availability of cutting-edge therapies in the region. Additionally, a burgeoning presence of local players such as Santen Pharmaceutical, Lupin Limited, and Taisho Pharmaceutical expands treatment choice and competitive landscape. Public health campaigns and increased screening programs have boosted early diagnosis rates, which further fuels demand for treatment solutions. Moreover, the expanding private healthcare sector and rising per capita healthcare expenditures enhance patient access and market penetration in Asia Pacific.

Dry Age Related Macular Degeneration Market Outlook for Key Countries

United States

The United States remains the cornerstone of the Dry AMD market due to its forefront role in innovation and comprehensive healthcare infrastructure. Several leading companies like Regeneron Pharmaceuticals and Novartis have significant operations in the U.S., driving the development and availability of therapies including investigational drugs and emerging digital diagnostic tools. Government programs such as Medicare provide broad coverage for eye care services, facilitating patient access. Additionally, the strong culture of clinical trials and partnerships with academic institutions further accelerate treatment advancements and adoption.

Japan

Japan's Dry AMD market benefits from a rapidly aging population and a healthcare system oriented towards sophisticated and specialized care. Companies such as Santen Pharmaceutical and Chugai Pharmaceutical play key roles in Japan's market dynamics, bringing both domestic and international innovations to patients. The government's proactive approach in supporting aging-related health issues and advanced regulatory frameworks streamline the introduction of new treatments. Additionally, high public awareness about eye health and regular screening programs underscore patient demand.

Germany

Germany continues to lead Europe's Dry AMD market through robust healthcare funding, widespread insurance coverage, and a strong presence of pharmaceutical giants such as Bayer AG and Boehringer Ingelheim. The country's comprehensive patient management systems and collaborative clinical research ecosystems foster steady advancements in treatment regimens. German regulations also provide clear pathways for introducing novel therapies, contributing to market stability and growth. Accessibility to specialized ophthalmologists and diagnostic centers is another critical factor reinforcing Germany's market position.

China

China's Dry AMD market is rapidly evolving, driven by expanding healthcare infrastructure and significant government support through initiatives targeting non-communicable diseases and aging-related conditions. Domestic companies like Lupin Limited (operating in India with increasing presence in China) and local biotech firms are increasingly involved in developing therapies tailored for the Asian population. Growing awareness campaigns and increasing urbanization are improving diagnosis and treatment rates. Furthermore, open trade policies and international partnerships accelerate technology inflow, making China one of the vibrant and fast-growing markets in the region.

South Korea

South Korea's Dry AMD market demonstrates strong growth potential backed by a technologically advanced healthcare system and significant investment in medical research. The government's emphasis on innovation and R&D spending encourages both multinational and domestic firms such as Samsung Bioepis and Hanmi Pharmaceutical to develop and commercialize novel treatment options. Enhanced patient awareness and growing elderly demographics stimulate demand, while the rapid adoption of next-generation diagnostic technologies helps improve early intervention outcomes, positioning South Korea as a key emerging market in Asia Pacific.

Market Report Scope

Market Segmentation

Therapeutic Type Insights (Revenue, USD, 2020 - 2032)

• Nutritional Supplements
• Anti-VEGF therapies
• Photobiomodulation
• Complement Inhibitors
• Stem Cell Therapy
• Others

Diagnostic Modality Insights (Revenue, USD, 2020 - 2032)

• Fundus Photography
• Optical Coherence Tomography (OCT)
• Fluorescein Angiography
• Ultrasonography
• Others

End User Insights (Revenue, USD, 2020 - 2032)

• Hospitals & Clinics
• Specialty Eye Care Centers
• Research Institutes
• Home Healthcare Settings
• Others

Regional Insights (Revenue, USD, 2020 - 2032)

• North America
• U.S.
• Canada
• Latin America
• Brazil
• Argentina
• Mexico
• Rest of Latin America
• Europe
• Germany
• U.K.
• Spain
• France
• Italy
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC Countries
• Israel
• Rest of Middle East
• Africa
• South Africa
• North Africa
• Central Africa

Key Players Insights

• Genentech
• Novartis AG
• Roche Holding AG
• Allergan (AbbVie)
• Alcon Inc.
• Bausch Health Companies
• Regeneron Pharmaceuticals
• Ipsen
• Neurotech Pharmaceuticals
• Acucela Inc.
• Ophthotech Corporation
• Gyroscope Therapeutics
• BioMarin Pharmaceutical
• Clearside Biomedical
• Kodiak Sciences
• Santen Pharmaceutical
• Olegos Inc.
• Ophthalmology Innovations Ltd.
• Astellas Pharma Inc.
• MeiraGTx